

Date :

To,

Smt. Jyoti J. Sardesai Director, Directorate of Food & Drugs Administration, 'Dhanwantari', Opposite Shrine of the Holy Cross, Bambolim – Goa - 403202

Sub : Regarding the ban on the drug 'Ranitidine'

Dear Madam,

We write to you on behalf of 'Arogya Sahaya Samiti'. We are a NGO of medical practitioners, RTI activists and like-minded citizens concerned with health of people and health related issues.

As per the news reports the Drug Controller General of India (DCGI) has alerted the state drug authorities to direct the manufacturers to ensure patient safety about 'Ranitidine' and to communicate to the DCGI at the earliest on the action initiated by them. (Ref. F.No. 12-03/19-DC (Safety-007 dated 23.9.2019)

We would like to know as to what action has been initiated in this matter, e.g. Any cheks/inspection/analysis carried out for raw material, manufacturers products, stored medicines etc.

So also during this intervening period the drug 'Ranitidine' is in sale and accessible to the general public at large who may not be aware of the carcinogenic effects of 'Ranitidine' and may be at potential risk. In the larger public interest we would also like to know as to what measures have been taken to caution the general public at large and measures taken to ensure their safety.

As this drug is very harmful for the health of patients, you are requested to ban this drug. The sale and use of the same should be stopped till further orders from the authorities as done in case of Directorate of Health, Government of Maharashtra.

In view of above we would appreciate FDA for providing us the information regarding action taken on the above important issues at the earliest.

Thanking you.

Yours faithfully

Dr. Manoj V. Solanki Founder Member, Arogya Sahaya Samiti.

Encl.: 1. Letter of Drug Controller General (India)